Jerry Y. Hsu - Genentech, Inc | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 33 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract 1964: Furmonertinib is a Brain-Penetrant EGFR TKI Highly Active in Uncommon EGFR Mutations, Including PACC and Exon 20 Insertions

Monique B. Nilsson,Zineb Mounir,Luna Musib,Junqin He,Xiaoxing Yu, Qing Li, Huibing Luo,John V. Heymach,Jerry Y. Hsu, Stuart Lutzker, Xiuning Le, Marcin Kowanetz

Cancer Researchno. 6_Supplement (2024): 1964-1964

引用0浏览0引用

Abstract CT152: FURTHER: A Global Study to Evaluate Furmonertinib in Patients with EGFR Mutant NSCLC Including Uncommon EGFR Mutations

Xiuning Le,Alexander I. Spira,Shirish M. Gadgeel,Yan Yu,Yanqiu Zhao,Ying Cheng,Jonathan W. Riess,Óscar Juan,Bo Gao,Kiyotaka Yoh,Martin Förster,Satoru Kitazono,Hidetoshi Hayashi,David Planchard,Yong Jiang, Jianyuan Huang,Nichole Baio,Marcin Kowanetz, Shirley Wang,William Leung,Jerry Y. Hsu,Jie Wang

Cancer Researchno. 7_Supplement (2024): CT152-CT152

引用0浏览0引用

PP01.24 FURVENT: Phase 3 Trial Testing Furmonertinib Vs Chemotherapy As First-Line Treatment for Advanced NSCLC with EGFR Exon 20 Insertions (FURMO-004)

Alexander Spira,Byoung Chul Cho,Enriqueta Felip,Edward B. Garon,Koichi Goto,Melissa Johnson,Natasha Leighl,Antonio Passaro, David Planchard,Sanjay Popat,James Yang, Xiaoqian Lu, Yong Jiang,Jack Huang,Morgan Lam, Marcin Kowanetz, Shirley Wang,John Le,Jerry Y. Hsu, Cai-Cun Zhou

Journal of Thoracic Oncologyno. 7 (2024): e17-e18

引用0浏览0引用

Supplementary Table S5. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Maura N. Dickler,Cristina Saura,Donald A. Richards,Ian E. Krop,Andrés Cervantes,Philippe L. Bedard,Manish R. Patel,Lajos Pusztai,Mafalda Oliveira,Alison K. Cardenas,Na Cui,Timothy R. Wilson,Thomas J. Stout,Michael C. Wei,Jerry Y. Hsu,José Baselga

crossref（2023）

引用0浏览0引用

Supplementary Table S2. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

crossref（2023）

引用0浏览0引用

Supplementary Figure S1. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

crossref（2023）

引用0浏览0引用

Supplementary Table S2. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

crossref（2023）

引用0浏览0引用

Supplementary Table S3. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

openalex（2023）

引用0浏览0引用

Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans

Shuguang Ma,Sungjoon Cho,Srikumar Sahasranaman,Weiping Zhao,Jodie Pang,Xiao Ding,Brian Dean, Bin Wang,Jerry Y Hsu,Joseph Ware,Laurent Salphati

Drug metabolism and disposition: the biological fate of chemicals（2023）

引用2浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn